"You'd be led to believe that you put in real-time pricing and a nice Web site and immediately get a 15% reduction in energy use, " says Accenture's Guthridge.
In the case of Avastin and Taxol, NICE says on its Web site it ended its appraisal of the combined drugs for metastatic breast cancer because it didn't receive a "full economic analysis" of the treatment from drugmaker Roche Products.
